Daniel Lang, a partner in Goodwin’s Technology Companies + Life Sciences Group, concentrates on start-up, general corporate, M&A and securities law matters and has significant experience in company formations, seed, venture and growth equity financings, mergers and acquisitions, capital markets transactions, SEC compliance and corporate governance. Mr. Lang represents public and private companies in diverse industries such as digital media, advertising technology, marketplace lending, fashion and beauty, music, Internet, mobile, enterprise software, biotechnology and medical diagnostics, as well as the venture capital and financial service firms that focus on these companies. He has experience advising companies through every stage of the corporate life cycle – from entity selection and initial financing through successful initial public offering or acquisition.

Mr. Lang was recognized as a New York Metro Rising Star by Super Lawyers in 2014, 2015 and 2016.




Mr. Lang’s representative clients include public companies: Foundation Medicine, Synchronoss Technologies, Ocera Therapeutics and Chiasma, as well as private companies: Glossier, Hubble Contacts, Noteworth, Paperless Post, Pond5, Celtra, Orchard, Megaphone TV, Proclivity Media, Reentry Games, Zive, Codiak BioSciences, Precision Biologics, Allena Pharmaceuticals, PatientBank, Syntimmune, TARA Biosystems and Linkwell Health.

Representative Matters

Repräsentative Angelegenheiten


Public Company Transactions
  • Chiasma, a late-stage biopharmaceutical company, in its $102 million initial public offering on the NASDAQ Stock Market
  • J.P. Morgan and Barclays Capital in the $184 million initial public offering of Intrexon Corporation, a synthetic biology company, on the NYSE
  • J.P. Morgan and BofA Merrill Lynch in the $116 million follow-on offering of Intrexon Corporation
  • JMP Securities in the $230 million follow-on offering of Intrexon Corporation
  • Cantor Fitzgerald in a $200 million “at the market” offering facility for Intrexon Corporation
  • Foundation Medicine, a cancer diagnostics company, in (i) its $120 million initial public offering on the NASDAQ Stock Market and (ii) its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion
  • Ocera Therapeutics, a biotechnology company, in its $28 million PIPE financing, $25 million public offering and $25 million “at the market” offering facility
  • Vivo Capital in its participation in a $12.5 million unit offering of BioPharmX
  • Vivo Capital, as lead investor, in a $35 million financing of Strongbridge Pharma
  • Represented Thar Pharmaceuticals, a biopharmaceutical company, in its acquisition by an affiliate of The Grünenthal Group
  • Songza, a streaming music company, in its sale to Google
  • M5 Networks, a cloud communications company, in its $146 million acquisition by ShorTel
  • XGraph, a social targeting company, in its acquisition by Add This (formerly Clearspring)
  • Fidelis Security Systems, a cybersecurity company, in its acquisition by General Dynamics
  • Nomi Technologies, a retail technology company, in its acquisition by Brickstream Corporation
  • Represented Tagman, the pioneer tag management and attribution company, in its acquisition by Ensighten
Venture Financings
  • Celtra in its $15.0 million financing by affiliates of WPP and Unilever
  • Syntimmune in its $50.0 million financing led by Apple Tree Partners
  • Glasswing Ventures as lead investor in an $8.3 million financing of Talla
  • PatientBank in its $2.2 million financing led by General Catalyst and Khosla Ventures with participation by SV Angels, Spectrum 28 and Data Collective
  • Hubble Contacts in its $16.5 million financing led by First Mark Capital, Greycroft, Two River and Wildcat Capital Management 
  • Glossier in its $24 million Series B financing led by Institutional Venture Partners, with participation from Index Ventures, Thrive Capital and Forerunner Ventures
  • Hubble Contacts in $7.2 million seed financings backed by Wildcat Capital Management, Two River, Founders Fund and Greycroft Partners
  • Aircall.io in its $8 million financing led by Baldteron Capital
  • Allena Pharmaceuticals in its $53 million Series C financing led by Partner Fund Management, Fidelity and Wellington
  • Codiak BioSciences in its $80 million financing led by Arch Venture Partners and Flagship Ventures
  • InterWest and Orbimed, as lead investors, in a $32 million investment round of Avedro
  • HYPR Brands in its $5 million financing led by Silvertech Ventures, Edgewater Equity and a number of other strategic investors.
  • Precision Biologics in its $50 million financing by an affiliate of NantWorks
  • Orchard Platform in its $30 million financing led by Thrive Capital, Spark Capital and Canaan Partners
  • Even Financial in its $2.8 million financing led by Canaan Partners and Lerer Hippeau Ventures
  • Into the Gloss (d/b/a Glossier) in its $8.4 million financing led by Thrive Capital
  • Pond5 in its $61 million financing by Accel Partners and Stripes Group
  • Paperless Post in its $25 million financing led by August Capital
  • Megaphone TV in its $4.3 million financing led by Softbank Korea
  • Nomi Technologies in its $10 million financing by Accel Partners, First Round Capital, Greycroft Partners and Forerunner
Professional Activities

Mr. Lang is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech and eLab NYC on venture financings and other elements of start-up law.

Professional Experience

Prior to joining Goodwin, Mr. Lang was an associate in the New York office of Heller Ehrman.


Mr. Lang was named a New York Metro Rising Star by Super Lawyers in 2014 and 2015. In law school, Mr. Lang was an articles editor of the Cardozo Law Review.

In The News

In den Nachrichten






J.D., 2006
Benjamin N. Cardozo School of Law

(cum laude)

B.A., 2003
Tufts University

(magna cum laude)



New York
New Jersey
Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte